key: cord-0931211-uwoz0k19
authors: Ren, Lu; Yu, Shandong; Xu, Wilson; Overton, James L; Chiamvimonvat, Nipavan; Thai, Phung N.
title: Lack of Association of Antihypertensive Drugs with the Risk and Severity of COVID-19: A Meta-Analysis
date: 2020-11-02
journal: J Cardiol
DOI: 10.1016/j.jjcc.2020.10.015
sha: d67e2af63dec5c65229767e2a15a7e307968323e
doc_id: 931211
cord_uid: uwoz0k19

BACKGROUND: The association of antihypertensive drugs with the risk and severity of COVID-19 remains unknown. METHODS AND RESULTS: We systematically searched PubMed, MEDLINE, The Cochrane Library, Cochrane Central Register of Controlled Trials (CENTRAL), ClinicalTrials.gov, and medRxiv for publications before July 13, 2020. Cohort studies and case-control studies that contain information on the association of antihypertensive agents including angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), calcium-channel blockers (CCBs), β-blockers, and diuretics with the risk and severity of COVID-19 were selected. The random-effects or fixed-effects models were used to pool the odds ratio (OR) with 95% confidence interval (CI) for the outcomes. The literature search yielded 53 studies that satisfied our inclusion criteria, which comprised 39 cohort studies and 14 case-control studies. These studies included a total of 2,100,587 participants. We observed no association between prior usage of antihypertensive medications including ACEIs/ARBs, CCBs, β-blockers, or diuretics and the risk and severity of COVID-19. Additionally, when only hypertensive patients were included, the severity and mortality were lower with prior usage of ACEIs/ARBs (overall OR of 0.81, 95% CI 0.66-0.99, p < 0.05 and overall OR of 0.77, 95% CI 0.66-0.91, p < 0.01). CONCLUSIONS: Taken together, usage of antihypertensive drugs is not associated with the risk and severity of COVID-19. Based on the current available literature, it is not recommended to abstain from the usage of these drugs in COVID-19 patients. REGISTRATION: The meta-analysis was registered on OSF (https://osf.io/ynd5g).

The 2019 coronavirus disease pandemic is caused by the novel and highly infectious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As of August 30, 2020, there were 25,099,237 confirmed cases globally and 844,176 deaths from the disease [1] . Emerging evidence has indicated a relatively elevated mortality in patients with preexisting cardiovascular comorbidities [ 2, 3 ] .

Viral infection occurs when the S protein of SARS-CoV-2 binds to the host angiotensinconverting enzyme 2 (ACE2) receptor to gain entry into the cells [4] . ACE2 serves a crucial role in the counter regulation of the blood pressure regulating system-the renin-angiotensinaldosterone system (RAAS) pathway-by primarily degrading angiotensin II to angiotensin-(1-7), thereby attenuating the effects of angiotensin II [5] . In patients with cardiovascular disease, ACE2 expression may be differentially regulated not only by diseased states [ 6, 7 ] , but also by commonly prescribed antihypertensive medications [8] [9] [10] [11] [12] .

Previous evidence has suggested that antihypertensive drugs such as angiotensinconverting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) can elevate ACE2 expression [8] [9] [10] , which may increase susceptibility to and worsen the prognosis of COVID-19. Due to the high prevalence of COVID-19 in patients with preexisting cardiovascular conditions such as hypertension [13] [14] [15] [16] , coronary artery disease, and congestive heart failure [17] , the usage of these antihypertensive drugs warrants great concerns. Indeed, controversy remains regarding the usage of these antihypertensive medications on the vulnerable population. We postulated that there may be an association between the usage of antihypertensive medications and the incidence and severity of COVID-19 due to the high mortality of patients with cardiovascular comorbidities.

To this end, we designed a meta-analysis to address whether there is an association of antihypertensive medications and the incidence and severity of COVID-19. In addition to ACEIs and ARBs, we also investigated other antihypertensive drugs [calcium channel blockers (CCBs), β-blockers, and diuretics] to evaluate whether these drugs may potentially be better substitutes for ACEIs/ARBs in the event that ACEIs/ARBs had a significant, negative association with COVID-19. We comprehensively searched through large databases to acquire relevant studies. We performed meta-analyses on 53 studies, 39 of which were cohort studies and the remaining 14 were case-control studies.

control studies that contain information on the association of antihypertensive agents including ACEIs, ARBs, CCBs, β-blockers, and diuretics, with the risk and severity of COVID-19. We systematically searched PubMed, MEDLINE, The Cochrane Library, the Cochrane Central Register of Controlled Trials (CENTRAL), ClinicalTrials.gov and medRxiv for publications before July 13, 2020. We also searched conference proceedings and performed manual reference list searching to acquire relevant papers.

Medical subject headings (MeSH) terms and keywords including randomized controlled trial, case-control study, cohort study, angiotensin-converting enzyme inhibitor, angiotensin II receptor blockers, calcium-channel blockers, beta-blockers, diuretics, anti-hypertensive agents, ACEIs, ARBs, coronavirus, 2019-nCoV, COVID-2019, and SARS-COV-2 were used. This review was not restricted to studies conducted in the English language; it includes reports from any countries that satisfy the inclusion criteria.

To be included in the analysis, the study had to fulfill the following criteria: 1) RCTs (open-label, single-blind, double-blind, or parallel group studies); 2) Cohort studies; 3) Case-control studies; 4) Studies that report anti-hypertensive medication data.

Studies were excluded from meta-analysis if they were: 1) Animal studies or in vitro studies; 2) Studies that did not report the usage of anti-hypertensive medications; 3) Full texts that could not be sourced; 4) Review papers; 5) Case reports; 6) Studies with unrelated outcomes or unreported outcomes; 7) Cross-sectional studies; 8) Clinical Trial Registries.

Bibliographic details and abstracts of all citations retrieved by the literature search were downloaded to Endnotes X9. All studies were screened and evaluated by two independent reviewers (LR, PNT), which were then checked by a third reviewer (SY). Discrepancies were resolved by discussion in group conferences. Completed data were then thoroughly checked by two additional reviewers (WX, JLO). Data including first author, year of publication, country where studies took place, study type, number of participants, number of hypertensive patients, age, sex, follow-up duration, type of antihypertensive drugs, and outcomes were extracted using a standardized form and presented in table format. We used the adjusted OR if the information was available from the studies. If the reports did not provide adjusted OR, we used the crude OR. We calculated all the crude ORs when not provided. We were unable to adjust for age, sex, and/or underlying conditions, due to lack of information from the studies. Additionally, some of the studies used hazard ratio (HR) or adjusted HR. Table 1 provides further information on which information was used for each study.

Newcastle-Ottawa Quality Assessment Scale was used to assess the quality of cohort studies and case-control studies. The assessment was performed by two independent reviewers (WX, JLO) and further checked by two additional reviewers (LR, PNT). Discussion was performed if obvious discrepancies existed in assigning the study quality assessment. An additional reviewer was consulted when necessary (SY). The completed information is provided in Online Tables 1 and  2. participants, but three trended more toward elderly participants [20] [21] [22] . Study durations varied, with the shortest being 14 days and the longest being 145 days. The outcomes of these studies included incidence, hospitalization, severity, and mortality. Incidence was defined as patients who took antihypertensive medications and tested positive for COVID-19, while severity was defined as a combination of hospitalization, intensive care unit (ICU) admission, and mortality. Severity was then further broken down into their individual components for analysis.

We performed meta-analyses on the incidence (26 studies), severity (40 studies), hospitalization (23 studies), ICU admission (12 studies), and mortality (38 studies) of COVID-19 in patients with prior usage of either ACEI, ARB, or a combination of both ( Figure 2) . As shown in the forest plots, there was no association with the incidence (overall OR of 0.96, 95% CI 0.86-1.08), severity (overall OR of 0.92, 95% CI 0.77-1.11), hospitalization (overall OR of 1.09, 95% CI 0.91-1.31), ICU admission (overall OR of 1.19, 95% CI 0.85-1.66), or mortality (overall OR of 0.92, 95% CI 0. 74-1.13) . Overall heterogeneity between trials was observed with incidence (I 2 =88.40%), severity (I 2 =83.08%), hospitalization (I 2 =70.27%), ICU admission (I 2 =56.64%), and mortality (I 2 =84.72%). Together, these data suggest that there was no association between prior drug usage and risk or severity of COVID-19 in patients taking ACEIs/ARBs.

We further conducted meta-analyses of severity and mortality of COVID-19 with prior usage of ACEIs, ARBs, or ACEI/ARBs in hypertensive patients (Figure 3 ). We observed a significant decrease in severity (overall OR of 0.81, 95% CI 0.66-0.99, p<0.05) and mortality (overall OR of 0.77, 95% CI 0.66-0.91, p < 0.01) in favor of ACEIs/ARBs. The heterogeneity between trials was observed with severity (I 2 =50.52%) and mortality (I 2 =46.96%). Together, these data suggest that prior usage of ACEIs/ARBs in hypertensive patients is associated with significantly lower severity and mortality than the control group.

We next examined whether prior usage of other antihypertensive medications exhibited an association with the risk and severity of COVID-19 (Figure 4) . There was no association between usage of CCBs with incidence (overall OR of 1.15, 95% CI 0.87-1.53) or severity (overall OR of 0.94, 95% CI 0.80-1.10) of COVID-19. Heterogeneity between trials was evident for both incidence (I 2 =93.61%) and severity (I 2 =17.11%). Similarly, there was no association between the use of β-blockers with incidence (overall OR of 1.03, 95% CI 0.78-1.35) or severity (overall OR of 1.23, 95% CI 0.74-2.04). There was heterogeneity in incidence (I 2 =92.59%) and severity (I 2 =85.42%) with β-blockers. Like CCBs and β-blockers, there was no evidence that prior usage of diuretics was associated with the incidence (overall OR of 0.86, 95% CI 0.54-1.38) or severity (overall OR of 0.96, 95% CI 0.81-1.15). Heterogeneity was also observed with diuretics and the incidence of COVID-19 (I 2 =97.26%). Together, there was no evidence for an association between prior usage of these antihypertensive medications and risk or severity of COVID-19 in patients taking any of these antihypertensive medications.

To assess publication bias, we constructed funnel plots of all the parameters that were tested (Online Figure 1) . Additionally, two independent reviewers performed the quality assessment, while two others confirmed results using the Newcastle-Ottawa Quality Assessment (Online Tables 1 and 2) . Finally, to determine if removing a study would skew the results, we performed sensitivity analyses on all the parameters that we examined in the main text. Results can be found in Online Figures 2-4.

The pandemic has disproportionately affected the lives of patients with cardiovascular comorbidities [17] . Although many variables may contribute to this outcome, we sought to address whether prior usage of antihypertensive medications is associated with the risk and severity of COVID-19 in this study. Our motivation stems from two factors. First, a previous study suggests that antihypertensive drugs may increase the expression of ACE2-a protein that is paramount for SARS-CoV-2 viral infection [4] . Second, there is high mortality in patients with cardiovascular complications [13] [14] [15] [16] .

We identified 53 studies that satisfied our inclusion criteria, which comprised 39 cohort and 14 case-control studies (Figure 1 ). The characteristics for these studies are detailed in Table  1 . The studies included a total of 2,100,587 patients. Meta-analyses were performed to determine the risk and severity of COVID-19 in patients with prior usage of ACEIs/ARBs. We observed no evidence of an association with regards to incidence, hospitalization, severity, and mortality. Since the findings in Figure 2 included both non-hypertensive and hypertensive patients, we determined whether there was an association of prior usage of these medications and the risk and severity of COVID-19 in hypertensive patients (Figure 3 ). We noted that severity (p<0.05) was significantly lower in hypertensive patients taking ACEIs/ARBs than controls. Additionally, mortality was significantly lower in patients taking ACEIs/ARBs versus control patients (p<0.01). These findings support the benefits of using ACEIs/ARBs in hypertensive patients. Therefore, our analyses suggest that abstaining from ACEIs/ARBs, especially in the context of hypertensive patients, will not provide benefits.

Additionally, we examined whether other commonly prescribed antihypertensive medications are associated with the risk and severity of COVID-19. There was no evidence of an association between taking these antihypertensive medications (CCBs, β-blockers, and diuretics) and the incidence and severity of COVID-19. With the leave-one-out-meta-analysis (Online Figures 2-4) , there were no significant differences in most of the parameters except for a significant increase in ICU admission, with more ACEIs/ARBs patients being admitted, when the study of Felice et al. was excluded (Online Figure 2 ) [19] . However, severity, a parameter that takes into account ICU admission, mechanical ventilation, duration of hospital stay, hospital admittance, noninvasive ventilation, and organ dysfunction, was not significantly different between ACEIs/ARBs and control patients. Therefore, caution is required for the interpretation of the ICU admission findings.

Multiple studies have reported high mortality in patients with cardiovascular complications [12] [13] [14] [15] . Our results suggest that taking antihypertensive medications did not increase the incidence or severity of COVID-19 in patients taking antihypertensive medications. In fact, ACEIs/ARBs may be beneficial in hypertensive patients. Our findings do not support abstaining from antihypertensive medications when patients are already taking them.

Additionally, it is critical to note that data regarding ACE2 expression with the usage of antihypertensive medications remains controversial, with some studies reporting an increase [8] [9] [10] [11] [12] , while others show no changes [ 23, 24 ] . Therefore, additional studies are required to test the effects of antihypertensive medications on ACE2 expression, as well as applicability of the findings across species. Current data support potential benefits compared to harms in the use of RAAS blockers in patients [25] . Our meta-analysis of currently available data further support the lack of an association between antihypertensive medications and the risk or severity of COVID-19.

Our current study provides several advantages relative to previous meta-analysis studies [26] [27] [28] [29] [30] [31] . In contrast to previous meta-analysis studies, which analyzed approximately 9-16 records, our study included 53 records to generate a large dataset. Additionally, while other studies primarily focused on assessing ACEIs/ARBs, our study included analyses of other antihypertensive drugs such as CCBs, β-blockers, and diuretics. New insights from the comprehensive meta-analysis in the current study have important implications in clinical decisions.

There are some limitations in the current study. Only observational studies are currently available in the literature due to the urgency of the pandemic resulting in the need to rapidly gather information. There were no available RCTs. Additionally, some studies did not provide ORs, necessitating the calculation of the values without adjustment for age, sex, and underlying comorbidities. Nonetheless, by taking advantage of meta-analysis on the large available and upto-date dataset of more than two million patients, these observational studies can be impactful to drive clinical decisions.

Based on all currently available literature, the usage of antihypertensive drugs is not associated with the risk and severity of COVID-19. It is not recommended to abstain from the use of these drugs in COVID-19 patients, especially those with hypertension. More clinical trials are needed to further validate these findings.

LR and PNT designed the study. LR and PNT screened and evaluated studies. LR and SY performed statistical analyses. PNT checked statistical analyses. LR, WX, JO, and PNT performed comprehensive characterization of studies. SY and NC provided expertise. LR, PNT, and NC wrote the manuscript. The corresponding authors had full access to all the data in the study and take responsibility for its integrity and the data analysis.

[76] Zhang P, Zhu L, Cai J, Lei F, Qin J-J, Xie J, et al. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ICU, intensive care unit.

We pooled data from ACEIs, ARBs, and a combination of ACEIs/ARBs to perform meta-analyses on the A) incidence, B) severity and C) mortality of COVID-19 in hypertensive patients. Statistics are provided in the forest plots.

ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker. 

An interactive web-based dashboard to track COVID-19 in real time

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19)

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Role of the ACE2/Angiotensin 1-7 Axis of the Renin-Angiotensin System in Heart Failure

ACE2 gene expression is up-regulated in the human failing heart

Circulating ACE2 activity correlates with cardiovascular disease development

Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2

Upregulation of Angiotensin-Converting Enzyme 2 After Myocardial Infarction by Blockade of Angiotensin II Receptors

Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? The Lancet Respiratory medicine

Enalapril attenuates downregulation of Angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat

Myocardial infarction increases ACE2 expression in rat and humans

Patients with arterial hypertension and COVID-19 are at higher risk of ICU admission

Meta-analysis investigating the relationship between clinical features, outcomes, and severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia

Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: A systematic review, metaanalysis and meta-regression

COVID-19 and comorbidities: a systematic review and meta-analysis

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the

Hospital Admission, and Intensive Care Among 2,026,227 United States Veterans Aged 54-75 Years

Use of RAAS inhibitors and risk of clinical deterioration in COVID-19: results from an Italian cohort of 133 hypertensives

Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19

Epidemiology, risk factors and clinical course of SARS-CoV-2 infected patients in a Swiss university hospital: an observational retrospective study

Nifedipine and Amlodipine Are Associated With Improved Mortality and Decreased Risk for Intubation and Mechanical Ventilation in Elderly Patients Hospitalized for COVID-19

Evidence against a major role for angiotensin converting enzyme-related carboxypeptidase (ACE2) in angiotensin peptide metabolism in the human coronary circulation

Combination reninangiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions

Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19

The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis

Treatment with ACE inhibitors or ARBs and risk of severe/lethal COVID-19: a meta-analysis. Heart

A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers

ACEI/ARB use and risk of infection or severity or mortality of COVID-19: A systematic review and meta-analysis

Estimation of Renin-Angiotensin-Aldosterone-System (RAAS)-Inhibitor effect on COVID-19 outcome: A Meta-analysis

Decreased Mortality of COVID-19 With Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Patients With Hypertension: A Meta-Analysis

Renin-Angiotensin-Aldosterone System Inhibitors and Outcome in Patients With SARS-CoV-2 Pneumonia: A Case Series Study

Assessment of clinical characteristics and mortality-associated factors in COVID-19 Critical cases in Kuwait

ACE-inhibitors and Angiotensin-2 Receptor Blockers are not associated with severe SARS-COVID19 infection in a multi-site UK acute Hospital Trust

Predictors of severe or lethal COVID-19, including Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers

Prior diagnoses and medications as risk factors for COVID-19 in a Los Angeles Health System

ARB/ACEI use and severe COVID-19: a nationwide case-control study

Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study

The effects of ARBs, ACEIs and statins on clinical outcomes of COVID-19 infection among nursing home residents

Reninangiotensin-aldosterone system inhibitors and COVID-19 infection or hospitalization: a cohort study

Pre-Existing Traits Associated with Covid-19 Illness Severity

COVID-19 with Different Severities: A Multicenter Study of Clinical Features

The Use of Adjuvant Therapy in Preventing Progression to Severe Pneumonia in Patients with Coronavirus Disease 2019: A Multicenter Data Analysis

Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality

Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study

Risk of severe COVID-19 in hypertensive patients treated with renin-angiotensinaldosterone system inhibitors

Association of previous medications with the risk of COVID-19: a nationwide claims-based study from South Korea

Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID-19 patients in Michigan, United States

Hypertension and Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19

Association of renin-angiotensin-aldosterone system inhibitors with COVID-19-related outcomes in Korea: a nationwide population-based cohort study

COVID-19 in Spain: age, Interleukin-6, C Reactive Protein and lymphocytes as key clues from a multicentre retrospective study

Associations with covid-19 hospitalisation amongst 406,793 adults: the UK Biobank prospective cohort study

Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers with the Risk of Hospitalization and Death in Hypertensive Patients with Coronavirus Disease-19

Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China

Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan

Association between renin-angiotensin system inhibitors and COVID-19 complications

Anti-hypertensive Angiotensin II receptor blockers associated to mitigation of disease severity in elderly COVID-19 patients

Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on COVID-19 in a western population. CARDIOVID registry

Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19)

Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension

Reninangiotensin system blockers and susceptibility to COVID-19: a multinational open science cohort study

Outcomes and Cardiovascular Comorbidities in a Predominantly African-American Population with COVID-19

Long-Term ACE Inhibitor/ARB Use Is Associated with Severe Renal Dysfunction and Acute Kidney Injury in Patients with severe COVID-19: Results from a Referral Center Cohort in the North East of France

Severe obesity is associated with higher in-hospital mortality in a cohort of patients with COVID-19 in the Bronx

BUT NOT MEDICATIONS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ARE ASSOCIATED WITH CORONAVIRUS DISEASE 2019

Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19

Characteristics and outcomes of a cohort of SARS-CoV-2 patients in the Province of Reggio Emilia

Could anti-hypertensive drug therapy affect the clinical prognosis of hypertensive patients with COVID-19 infection? Data from centers of southern Italy

Association between chronic ACE inhibitor exposure and decreased odds of severe disease in patients with COVID-19

Associations between Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blocker Use, Gastrointestinal Symptoms, and Mortality among Patients with COVID-19. Gastroenterology

Clinical impact of renin-angiotensin system inhibitors on in-hospital mortality of patients with hypertension hospitalized for COVID-19

Characteristics, outcome and predictors of in-hospital mortality in an elderly population from a SARS-CoV-2 outbreak in a long-term care facility

Role of Drugs Affecting the Renin-Angiotensin-Aldosterone System on Susceptibility and Severity of COVID-19: A Large Case-Control Study from Zheijang Province, China

Effects Of ARBs And ACEIs On Virus Infection, Inflammatory Status And Clinical Outcomes In COVID-19 Patients With Hypertension: A Single Center Retrospective Study. Hypertension. 0

Hypertension in patients hospitalized with COVID-19 in Wuhan, China: A single-center retrospective observational study